Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04288687 | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects | completed | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT01409200 | Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | completed | Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 |
| clinicaltrials |
| NCT04443062 | Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer(Bullseye) | completed | Phase 2 | 58 | Radboud University Medical CenterOTHER | 2 | Feb 27, 2026 | clinicaltrials |
| NCT06056791 | Study of INKmune in Patients With mCRPC (CaRe Prostate)(CaRe) | completed | Phase 1 / Phase 2 | 12 | Inmune Bio, Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT01314118 | IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen | completed | Phase 2 | 131 | Janssen Biotech, Inc.INDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT03568188 | Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer(FOCALE) | completed | Phase 2 | 174 | Hospices Civils de LyonOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT00809991 | Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate | completed | Phase 2 | 91 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03421782 | Fatigue Interventions in Cancer (Exercise Intervention) | completed | Phase 2 | 126 | University of UtahOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06661902 | Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial(BURN) | completed | Phase 1 / Phase 2 | 350 | University of WashingtonOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT01543659 | Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 77 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT02274779 | Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer(OLIGOPELVIS) | completed | Phase 2 | 74 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT01517451 | Radiation and Androgen Ablation for Prostate Cancer | completed | Phase 1 / Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03338790 | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer(CheckMate 9KD) | completed | Phase 2 | 292 | Bristol-Myers SquibbINDUSTRY | 11 | Jan 27, 2026 | clinicaltrials |
| NCT03565835 | Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer | completed | Phase 2 | 31 | Montefiore Medical CenterOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT03503344 | Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer(PILLAR) | completed | Phase 2 | 26 | University of California, San FranciscoOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03556904 | FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE) | completed | Phase 2 | 14 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT04717154 | Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer(INSPIRE) | completed | Phase 2 | 69 | Radboud University Medical CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT02854436 | An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies(Galahad) | completed | Phase 2 | 289 | Janssen Research & Development, LLCINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT02985957 | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)(CheckMate 650) | completed | Phase 2 | 351 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 22, 2025 | clinicaltrials |
| NCT04037358 | RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers(RAVENS) | completed | Phase 2 | 64 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT00117286 | Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer | completed | Phase 2 / Phase 3 | 57 | Ferring PharmaceuticalsINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT03007732 | Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT | completed | Phase 2 | 23 | David OhOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT01089387 | Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction(INSTIN) | completed | Phase 1 / Phase 2 | 18 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | completed | Phase 1 / Phase 2 | 43 | NantCell, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03480646 | ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 175 | Constellation PharmaceuticalsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT02203695 | Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | completed | Phase 2 | 86 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT03939689 | I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).(ARROW) | completed | Phase 2 | 120 | Progenics Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 14, 2025 | clinicaltrials |
| NCT04838626 | Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection(GuideView) | completed | Phase 2 / Phase 3 | 195 | Novartis PharmaceuticalsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT03493945 | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) | completed | Phase 1 / Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03516812 | Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 36 | University of WashingtonOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04158245 | 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies | completed | Phase 2 | 9 | Tulane UniversityOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT03098836 | Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer(PANTHER) | completed | Phase 2 | 93 | Daniel George, MDOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05230251 | Radioligand fOr locAl raDiorecurrent proStaTe cancER(ROADSTER) | completed | Phase 1 / Phase 2 | 3 | Glenn BaumanOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07161778 | A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer(TRICREST) | completed | Phase 2 | 55 | Barts & The London NHS TrustOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT00924027 | A Study of Patients Receiving High-Dose Rate Brachytherapy | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03458247 | Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer(OPTIMABI) | completed | Phase 2 | 94 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05946603 | IS-002 Phase 2 Prostate Cancer Study | completed | Phase 2 | 59 | Intuitive SurgicalINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT02874014 | Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer | completed | Phase 2 | 56 | Mayo ClinicOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05137561 | Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)(PROBIOP) | completed | Phase 2 / Phase 3 | 217 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT04381832 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 173 | Arcus Biosciences, Inc.INDUSTRY | 2 | Jul 22, 2025 | clinicaltrials |
| NCT03448458 | Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 17 | Emory UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT02430480 | Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04621500 | Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans(VitD/RNA-seq) | completed | Phase 2 | 60 | Medical University of South CarolinaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03315871 | Combination Immunotherapy in Biochemically Recurrent Prostate Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2025 | clinicaltrials |
| NCT02903368 | Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy | completed | Phase 2 | 118 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06312670 | Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | completed | Phase 2 | 13 | Pedro Barata, MD, MScOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06389695 | Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients | completed | Phase 1 / Phase 2 | 20 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT04390880 | 18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer(PROSPYL) | completed | Phase 2 | 239 | VA Greater Los Angeles Healthcare SystemFED | 1 | May 16, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 4, 2026source: clinicaltrials